Experimental Cancer Drug Shows Potential to Improve Tuberculosis Treatment

Researchers at Johns Hopkins Medicine have found that an experimental drug, currently in cancer clinical trials, may enhance standard tuberculosis (TB) treatments by encouraging infected cells to die through a more controlled process. Their study, published in Nature Communications, suggests that this approach could make TB therapies more effective and reduce lung damage in survivors, potentially lowering the risk of long-term lung dysfunction known as post-TB lung disease.

TB, caused by the bacterium Mycobacterium tuberculosis, remains a major global health concern, with an estimated 1.25 million deaths and 10.8 million new cases in 2023. Many infections are resistant to standard antibiotics, making treatment more challenging. Standard TB therapy relies on a combination of antibiotics, but these regimens are lengthy, costly, and can leave patients vulnerable to relapse and lung scarring.

In early TB infection, lung cells use apoptosis—a regulated form of cell death—to contain the bacteria. However, as the disease progresses, the bacteria shift cell death toward necrosis, which causes inflammation and tissue damage. This shift is driven by the bacteria prompting host cells to produce Bcl-2 proteins, which block apoptosis.

The research team tested whether inhibiting Bcl-2 with navitoclax, a drug in cancer trials, could improve TB outcomes in mice. Mice treated with both navitoclax and standard TB antibiotics (rifampin, isoniazid, and pyrazinamide) showed a 40% reduction in lung necrosis and scarring, and a 16-fold greater decrease in bacterial burden compared to those given antibiotics alone. Navitoclax alone had no effect on the bacteria.

These findings indicate that adding navitoclax to TB treatment could reduce lung damage and improve recovery. Further clinical trials will be needed to determine if these results translate to human patients and if this approach could benefit those with other chronic bacterial infections.